Communiqués Avalo Therapeutics, Inc.

Actions

AVTX

US05338F3064

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 15:32:08 15/07/2026			Varia. 5j.	Varia. 1 janv.
18,15 ^USD	-1,47%		-4,31%	+1,43%

26/06	Avalo Therapeutics intègre les indices Russell 2000 et Russell 3000	MT
23/06	Avalo Therapeutics, Inc. annonce la nomination de Ron Philip à son conseil d'administration	CI

Communiqués

07/07	Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum	AQ
26/06	Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes	AQ
23/06	Avalo Therapeutics Appoints Ron Philip to Board of Directors	AQ
16/06	Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody	AQ
22/05	Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)	AQ
13/05	Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates	AQ
06/05	Avalo Therapeutics Announces Pricing of $375 Million Public Offering	AQ
06/05	Avalo Therapeutics : Topline Results from the Phase 2 LOTUS Study of Abdakibart in Moderate to Severe Hidradenitis Suppurativa (HS)	PU
05/05	Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants	AQ
05/05	Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa	AQ
28/04	Avalo Therapeutics Purchases Optional Milestone Buyout	AQ
23/03	Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates	AQ
24/02	Avalo Therapeutics to Participate in Upcoming Investor Conferences	AQ
18/02	Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)	AQ
04/02	Avalo Therapeutics to Participate in Upcoming Investor Conferences	AQ
17/11	Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)	AQ
06/11	Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates	AQ
03/11	Avalo Therapeutics to Participate in Upcoming Investor Conferences	AQ
29/10/25	Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa	AQ
10/10/25	Avalo Therapeutics : October 2025 Corporate Presentation	PU
01/10/25	Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources	AQ
22/09/25	Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors	AQ
27/08/25	Avalo Therapeutics to Participate in Upcoming Investor Conferences	AQ
07/08/25	Avalo Therapeutics : August 2025 Corporate Presentation	PU
07/08/25	Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates	AQ